MedCity News
OCTOBER 31, 2023
While legacy pharma companies battle in court with government agencies over how to address the costs that result from antiquated drug development paradigms, a growing cadre of compute-enabled life science companies are unlocking the nascent power of next-generation compute technologies to transform drug discovery and development.
Fierce Pharma
OCTOBER 30, 2023
Editor's note: This story has been updated with a comment from Pfizer. An earlier version of the story stated that nearly 800 jobs would be affected. | After plunging COVID revenues prompted Pfizer to embark on a cost-cutting crusade, more details about the company's savings efforts are coming into focus.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
NOVEMBER 1, 2023
Bayer launches support tool for diabetic kidney disease Phil.
PharmaTimes
NOVEMBER 3, 2023
Since 2022, an estimated 17,000 strokes and 4,000 deaths have been prevented - News - PharmaTimes
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
MedCity News
OCTOBER 30, 2023
The vast majority of healthcare data isn’t used because it’s difficult to work with, according to Beth Andrews, chief digital health officer of life sciences and healthcare at Dell Technologies. Andrews made these comments during a session at the MedCity News INVEST Digital Health conference.
Fierce Pharma
NOVEMBER 3, 2023
Pfizer’s plunging COVID-19 product demand has spurred a companywide cost-cutting campaign, with nearly 200 jobs now on the chopping block in Michigan. | Pfizer is cutting roughly 200 positions at its Kalamazoo site following a review of demand for its COVID-19 vaccine and antiviral Comirnaty and Paxlovid.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
PharmaTimes
OCTOBER 31, 2023
Around 400,000 eligible patients are set to benefit from the travel offer - News - PharmaTimes
MedCity News
OCTOBER 29, 2023
AI technologies have a role in the life sciences that goes beyond drug discovery. A panel at the MedCity News INVEST conference in Dallas discussed how new tech platforms help speed up the process of recruiting patients and running clinical trials.
Fierce Pharma
OCTOBER 31, 2023
For Pfizer, several years of pandemic megaprofits have soured as overstocked COVID-19 drugs and vaccines take a major toll on the drug behemoth’s financials. | Pfizer's pandemic megaprofits have soured as overstocked COVID-19 drugs and vaccines take a major toll on the drug behemoth’s financials.
pharmaphorum
NOVEMBER 1, 2023
Imfinzi faces Keytruda competition in biliary tract cancer Phil.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Copyright Clearance Center
OCTOBER 31, 2023
Oct. 31, 2023 – Danvers, Mass. – CCC , a pioneer in voluntary collective licensing and leading information solutions provider, held its annual ‘We Not Me’ global volunteering event as part of a year-round charity initiative about demonstrating the power of individual action to build community and support the common good. CCC US-based staff collaborated with colleagues in various parts of the country including Massachusetts, New Hampshire, Rhode Island, Oregon, Washington, and California, serving
MedCity News
OCTOBER 29, 2023
Providers who don’t take advantage of AI will get “left behind,” said Dr. Shantanu Gaur, founder and CEO of Allurion Technologies, during a panel discussion at INVEST Digital Health.
Fierce Pharma
NOVEMBER 2, 2023
The days of booming COVID-19 vaccine sales, which sent Moderna into the ranks of pharma's top companies, have | The company is focusing on scaling back its manufacturing efforts to cope with the lack of COVID-19 vaccine demand.
European Pharmaceutical Review
NOVEMBER 2, 2023
While unsolicited and burdensome, medicine shortages are an obstacle faced by the pharmaceutical industry. In 2023, a combination of factors, including increased demand (particularly for critical medicines), economic inflation, as well as international geopolitical unrest, has led to Europe’s supply chain being acutely affected. Consequently, regulators, trade groups and other organisations have worked to prevent and alleviate medicine shortages in the region.
PharmaVoice
NOVEMBER 1, 2023
From hallucinations to data privacy, pharma looks to iron out the kinks of generative AI.
MedCity News
OCTOBER 30, 2023
Value-based care and data are areas to be excited about in the employee benefits space, executives shared during a panel discussion at the MedCity News INVEST Digital Health conference.
Fierce Pharma
NOVEMBER 1, 2023
The FDA has signed off on Amgen’s biosimilar version of Johnson & Johnson’s autoimmune standout Stelara. | The FDA has approved Amgen’s biosimilar version of Johnson & Johnson’s autoimmune standout Stelara. But the new product will not launch until 2025 because of a settlement the companies made earlier this year, which delayed the launch in exchange for J&J dropping a patent infringement lawsuit.
European Pharmaceutical Review
NOVEMBER 1, 2023
In July 2022, the World Health Organization (WHO) released its inaugural report on the pipeline of vaccines currently in development to prevent infections caused by antimicrobial resistance (AMR) bacterial pathogens. 1 WHO’s analysis was stark. It asserted the need to accelerate trials for AMR-related vaccines in late‑stage development and maximise the use of those already on the market.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
pharmaphorum
NOVEMBER 3, 2023
Study finds higher cancer rate in patients given ‘all clear’ Phil.
MedCity News
NOVEMBER 1, 2023
While telemedicine seems to be the ideal solution to this ever-increasing shortage problem, it still has challenges and benefits that need to be considered before deciding to add a telemedicine program of your own.
Fierce Pharma
OCTOBER 31, 2023
As several new JAK inhibitors threaten Incyte’s bread-and-butter Jakafi in myelofibrosis, the company is busy advancing new regimens ahead of the drug’s 2028 patent cliff. | As several new JAK inhibitors threaten Incyte’s bread-and-butter Jakafi in myelofibrosis, the company is busy advancing new regimens ahead of the drug’s 2028 patent cliff.
European Pharmaceutical Review
OCTOBER 30, 2023
Echoes of the global health challenges we faced during the COVID-19 pandemic still linger as new variants emerge and COVID continues to make headlines. A question that continues to sit in the back of many people’s minds is what happens if there is another outbreak or global pandemic? Are we preparing and how ready are we for the next one? Vaccitech’s Chief Business Officer, Graham Griffiths, discusses key learnings in drug and vaccine development , the challenges of preparing for the unknown, an
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
pharmaphorum
OCTOBER 30, 2023
EMA finds no evidence GLP-1 agonists cause thyroid cancer Phil.
MedCity News
NOVEMBER 1, 2023
In a letter to Senate leadership, several organizations asked for the passing of legislation that would reform the patent system and improve competition in the prescription drug space.
Fierce Pharma
OCTOBER 31, 2023
For 170 million euros plus royalties, Galapagos has transferred Jyseleca and its operations to Alfasigma. The deal includes 400 employees who will transfer to Alfasigma.
PharmaTimes
NOVEMBER 2, 2023
The NHS has already delivered over 20 million winter vaccines this year - News - PharmaTimes
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
pharmaphorum
NOVEMBER 2, 2023
Sangamo sheds staff once again in another retreat Phil.
MedCity News
OCTOBER 31, 2023
Several senators wrote a letter to the Biden Administration asking for action that ensures coverage of over-the-counter birth control without the need for a prescription. The letter was led by Senators Patty Murray (D-Washington), Tammy Baldwin (D-Wisconsin), Bernie Sanders (I-Vermont) and Ron Wyden (D-Oregon).
Fierce Pharma
OCTOBER 30, 2023
After Bristol Myers Squibb’s space odyssey earlier this year, another pharmaceutical major is pushing drug development to the fringes of Earth’s gravitational pull. | Eli Lilly is entering the orbit of Redwire Corporation to test the latter company's in-space drug manufacturing platform. The technology will be sent to the International Space Station aboard a SpaceX mission set to launch sometime after Nov. 5.
Pharmaceutical Technology
NOVEMBER 2, 2023
Memo’s fast track-designated candidate is currently in a Phase II trial for BKV infection, with a data readout expected in 2024.
Expert insights. Personalized for you.
131 
Let's personalize your content